The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Innovation in Pharmaceuticals: Tetrapeptide derivatives. Buy the report here.

Smarter leaders trust GlobalData

However, not all innovations are equal and nor do they follow a constant upward trend. Instead, their evolution takes the form of an S-shaped curve that reflects their typical lifecycle from early emergence to accelerating adoption, before finally stabilising and reaching maturity.

Identifying where a particular innovation is on this journey, especially those that are in the emerging and accelerating stages, is essential for understanding their current level of adoption and the likely future trajectory and impact they will have.

110 innovations will shape the pharmaceutical industry

According to GlobalData’s Technology Foresights, which plots the S-curve for the pharmaceutical industry using innovation intensity models built on over 756,000 patents, there are 110 innovation areas that will shape the future of the industry.

Within the emerging innovation stage, cell therapy for ocular disorders, coronavirus vaccine components, and DNA polymerase compositions are disruptive technologies that are in the early stages of application and should be tracked closely. Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Innovation S-curve for the pharmaceutical industry

Tetrapeptide derivatives are a key innovation area in the pharmaceutical industry

Tetrapeptides are classified as oligopeptides as they contain only four amino acids linked by peptide bonds. Several tetrapeptides are pharmacologically active, showing affinity and specificity for multiple receptors in protein-protein signalling. In nature, tetrapeptides (CTPs) are both linear and cyclic, with the latter mimicking reverse turns commonly found on the surfaces of proteins and targets for drug therapy. The tetrapeptide derivatives L-lysine-L-arginine-L-aspartic acid-L-serine (tetrapeptide A) and di-tert.butyloxycarbonyl-L-lysine-L-arginine-L-aspartic acid-tert.butyl O-tert.butyl-L-serinate (tetrapeptide B) have demonstrated optimal cardioprotective effect. Tetrapeptide derivative PEP1261 (BOC-Lys(BOC)-Arg-Asp-Ser(tBu)-OtBU), a peptide sequence (39-42) of lactoferrin inhibited the effect on the ROS generation as well as in mRNA synthesis and expression of complement factors in neutrophils isolated from infarct heart.

GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 170+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of tetrapeptide derivatives.

Key players in the tetrapeptide derivatives space – a notable innovation area in the pharmaceutical industry

‘Application diversity’ measures the number of different applications identified for each relevant patent and broadly splits companies into either ‘niche’ or ‘diversified’ innovators.

‘Geographic reach’ refers to the number of different countries each relevant patent is registered in and reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.

Patent volumes related to tetrapeptide derivatives space

Company Total patents (2010 - 2022) Premium intelligence on the world's largest companies
Amgen 317 Unlock Company Profile
Bristol-Myers Squibb 281 Unlock Company Profile
F. Hoffmann-La Roche 274 Unlock Company Profile
Vertex Pharmaceuticals 160 Unlock Company Profile
Gilead Sciences 155 Unlock Company Profile
Morningside Group 138 Unlock Company Profile
Berkshire Hathaway 114 Unlock Company Profile
Enanta Pharmaceuticals 110 Unlock Company Profile
Merck & Co 110 Unlock Company Profile
Helix BioMedix 83 Unlock Company Profile
Curis 63 Unlock Company Profile
Abliva 57 Unlock Company Profile
Ministry of Trade and Industry, Singapore 55 Unlock Company Profile
Sanofi 53 Unlock Company Profile
AbbVie 50 Unlock Company Profile
GemVax & KAEL 49 Unlock Company Profile
Cara Therapeutics 49 Unlock Company Profile
Lumosa Therapeutics 45 Unlock Company Profile
Ambrx Biopharma 45 Unlock Company Profile
Ipsen 42 Unlock Company Profile
Centre National de la Recherche Scientifique 42 Unlock Company Profile
E. Merck 42 Unlock Company Profile
C. H. Boehringer Sohn 40 Unlock Company Profile
International Flavors & Fragrances 39 Unlock Company Profile
Palatin Technologies 39 Unlock Company Profile
Nanjing Xinjiekou Department Store 39 Unlock Company Profile
Cytogel Pharma 38 Unlock Company Profile
Ashland Incorporated 34 Unlock Company Profile
viDA Therapeutics 33 Unlock Company Profile
Jiangsu Hengrui Medicine 31 Unlock Company Profile
CMS Peptides Patent Holding Company 31 Unlock Company Profile
Techfields 30 Unlock Company Profile
Lonza Group 30 Unlock Company Profile
Dr. Wolff Gruppe 28 Unlock Company Profile
Sutro Biopharma 27 Unlock Company Profile
Riptide Bioscience 27 Unlock Company Profile
Lundbeck Foundation 26 Unlock Company Profile
Kotobuki Realty 26 Unlock Company Profile
Avixgen 24 Unlock Company Profile
United Nations Industrial Development Organization 24 Unlock Company Profile
ValiRx 23 Unlock Company Profile
Arrowhead Pharmaceuticals 22 Unlock Company Profile
Tao Health Life Pharma 22 Unlock Company Profile
Caregen 21 Unlock Company Profile
Children's Medical Center 21 Unlock Company Profile
Asahi Group Holdings 21 Unlock Company Profile
Rohto Pharmaceutical 21 Unlock Company Profile
MannKind 21 Unlock Company Profile
US Department of Health and Human Services 21 Unlock Company Profile
Nutcracker Therapeutics 20 Unlock Company Profile

Source: GlobalData Patent Analytics

Amgen is the leading patent filer of tetrapeptide derivatives. Amgen develops, manufactures, and markets innovative human medicines to treat patients suffering from serious diseases. It develops novel medicines in six focused disease areas including cardiovascular diseases, oncology/haematology, inflammation, bone health, neurological disorders and nephrology. Carfilzomib (Kyprolis), an approved treatment for multiple myeloma, is a synthetic tetrapeptide developed by Amgen. Amgen is headquartered in Thousand Oaks, California, US. Other players in the space include Bristol-Myers Squibb and F. Hoffmann-La Roche with key patent filed by both companies for tetrapeptide derivatives as potential drug targets.

In terms of application diversity, Aeterna Zentaris is the top company, followed by Dr. Wolff Gruppe and A. Menarini Industrie Farmaceutiche Riunite. By means of geographic reach, Curis holds the top position. Whilst Abliva and Ambrx Biopharma stand in second and third positions, respectively.

To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.